Pediatrix Medical Group, Inc. (MD)

Over the past six months, Pediatrix Medical Group's stock has experienced fluctuations, including a price increase to $21.69 by April 6, 2026, and a subsequent decline of over 7.75% by May 5, 2026. The company reported its first-quarter 2026 earnings on May 5, 2026, with an Adjusted EPS of $0.44 on revenue of $476.20 million. Pediatrix acquired Tennessee Maternal-Fetal Medicine in late March 2026 and hired Dr. James Barry and Dr. Jochen Profit. During the first quarter of 2026, the company repurchased 1 million shares of its stock for $21 million.

Demand for Pediatrix Medical Group's products and services exhibits seasonality, with the healthcare staffing sector typically experiencing a decline in both earnings and revenue sequentially from the fourth quarter to the first quarter.

Pediatrix Medical Group, Inc. is a national medical group specializing in healthcare for women, babies, and children, operating within the Health Services sector. They offer a range of services, including maternal care, intensive care for premature babies, cardiology care, and anesthesia care. The company focuses on high-quality, evidence-based care and invests in research, education, quality improvement, and safety initiatives.

Pediatrix Medical Group, Inc. has a significant national presence across the United States, treating patients in 42 states and territories and billing for services in 37 states. The company operates over 1,190 locations and partners with nearly 400 hospitals, with its corporate headquarters in Sunrise, Florida.

Pediatrix Medical Group's brand reputation has seen positive developments, including an upgrade of its issuer credit rating to 'BB' by S&P Global Ratings in November 2025. The company's rebranding from MEDNAX to Pediatrix Medical Group in March 2022 aimed to unify its clinical expertise. The appointments of Dr. James Barry and Dr. Jochen Profit in March 2026 are expected to further enhance the company's reputation.

Pediatrix Medical Group, Inc. is largely institutionally owned, with approximately 70.05% of the company's stock held by institutional investors. BlackRock, Inc. holds approximately 16.2% of shares, and The Vanguard Group, Inc. holds about 10.8%. Insiders hold 1.28%, and public companies and individual investors hold 28.68%.